QIAGEN is a provider of sample and assay technologies for molecular diagnostics, analytics as well as for academic and pharmaceutical research.
In the field of molecular diagnostics, syndromic testing allows to detect multiple pathogens in a single test run. With the QIAstat-Dx Rise platform, QIAGEN aims to offer large hospitals and laboratories a high-throughput system for syndromic testing.
The platform enables customers to increase testing efficiency and extend walk-away time. This is made possible by a loading and robotics system that automatically recognizes the sample types in the cartridges, digitally tracks and prioritizes the cartridges and supports the immediate execution of urgent tests at any time.
Services
Industries
Key Figures
- IVDR instrument as a closed system without manual intervention. With a random access option, it can deliver up to 160 tests per day
- Sample storage for two hour walk-away time
- Use of a camera system with versatile vision algorithms to enable sample and cartridge identification
- Camera-based self-calibration for maximum accuracy and reproducibility
- Internal temperature management to ensure maximum utilization of the sample stability time
Our Contribution
The design and development of the QIAstat-Dx Rise platform was carried out by Helbling in close coordination with QIAGEN. Helbling’s industrial designers and engineers were able to develop a benchtop system that met QIAGEN's product requirements in terms of industrial design and user-friendliness. The feasibility and subsequent realization were successfully implemented in close interdisciplinary work. The manufacturer was involved in the project at an early stage to ensure a smooth design transfer. After the market launch, Helbling continued to provide support as part of life cycle management.
The following services were provided by Helbling:
- Deriving the requirements for the platform and the specifications for the instrument and the individual modules
- Designing and evaluating system concepts
- Creating the electronics, mechanics, and firmware
- Development support for the application software
- Elaborating the test criteria and test protocols
Outcome
The successful product development of the QIAstat-Dx Rise platform for the regulated market enables QIAGEN to further expand in the fast-growing syndromic testing market. It only took 20 months from the product vision to successful verification. This was possible thanks to our many years of experience in laboratory automation, close cooperation based on trust, just-in-time development and production and finding pragmatic solutions.
